© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
William J. Gradishar, MD, discusses advances in the last year in the treatment of patients with HER2-positive breast cancer.
William J. Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses advances in the last year in the treatment of patients with HER2-positive breast cancer.
<<<